An Engineered Probiotic Produces a Type III Interferon IFNL1 and Reduces Inflammations in in vitro Inflammatory Bowel Disease Models

[Image: see text] The etiology of inflammatory bowel diseases (IBDs) frequently results in the uncontrolled inflammation of intestinal epithelial linings and the local environment. Here, we hypothesized that interferon-driven immunomodulation could promote anti-inflammatory effects. To test this hyp...

Descripción completa

Detalles Bibliográficos
Autores principales: Chua, Koon Jiew, Ling, Hua, Hwang, In Young, Lee, Hui Ling, March, John C., Lee, Yung Seng, Chang, Matthew Wook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10498420/
https://www.ncbi.nlm.nih.gov/pubmed/36399014
http://dx.doi.org/10.1021/acsbiomaterials.2c00202

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10498420/
https://www.ncbi.nlm.nih.gov/pubmed/36399014
http://dx.doi.org/10.1021/acsbiomaterials.2c00202

Ejemplares similares